View AMCP letter urging Congress to support 12-month continuous eligibility for adults in Medicaid and the Children’s Health Insurance Program (CHIP) by passing the Stabilize Medicaid and CHIP Coverage Act
On Aug. 12, CMS issued a Final Notice on Transitional Coverage for Emerging Technologies. Access the NewsBREAK to learn more.
Meet Adrian Washington, VP of Client Management at a pharmaceutical company and AMCP member for more than 20 years.
Meet Maher Abdel Sattar, FAMCP, MS, PharmD, a volunteer with AMCP for over 15 years and currently an Associate Director of Affairs Operations at a Pharmaceutical Company.
Meet Macy Meng, an AMCP Student Pharmacist Committee Chair (2024-2025) and AMCP member since 2023.
View AMCP comments to the FDA on considerations in demonstrating biosimilar interchangeability with a biologic reference product.
View AMCP comments in response to the 21st Century Cures 2.0 Request for Information.
With 102 days to go until the 2024 general election, the race for the Oval Office is shaping up as a race to the finish between Vice President Kamala Harris and Republican Donald Trump. AMCP’s 2024 Election Outlook provides an in-depth look at the top-of-the-ticket candidates, forecast analyses for House, Senate, and gubernatorial elections, and critical information about the state of US politics. Source: Tiber Creek
With Vice President Kamala Harris likely to receive the Democratic nomination, we outline the health policy positions she has supported as a Senator, Vice President, and in her 2020 presidential campaign.
AMCP's Tom Casey gives a recap on the House Committee on Oversight and Accountability hearing, “The Role of Pharmacy Benefit Managers in Prescription Drug Markets Part III: Transparency and Accountability.”
